Mr. Donald E. Rindell, also known as Don, has been a Senior Director of Business Development at Amylin Pharmaceuticals, Inc., since 2005. Before moving to Amylin, Mr. Rindell served the industry as a highly sought-after independent consultant. Mr. Rindell has a successful consulting practice, during which time he served as Acting President of Medical Device Group, Inc., an acute care and respiratory company, Vice President of Business Development of CardioNet, Inc., a 'real-time'' 24/7 cardiovascular monitoring company and Vice President of Business Development of HandyLab, Inc., a molecular diagnostics and pharmacogenomics system company. His responsibilities included corporate marketing, mergers and acquisitions activities, product planning and new strategic initiatives. Prior to his consulting practice, he served as Vice President of Corporate Development & Strategic Planning of Advanced Tissues Sciences, Inc. ('ATS''), a La Jolla, California-based biotechnology company. Prior to his tenure at ATS, Mr. Rindell served as the Vice President for Global Business Management of Braun/Thermoscan, a division of The Gillette Company. At Braun/Thermoscan, he played a major role in building its medical diagnostics business. Mr. Rindell served as Executive Director of Sales and Marketing at Hybritech, a division of Eli Lilly. He has been a Director at TearLab Corporation since March 2006. He has been a Director of TearLab Inc., since March 2006. Mr. Rindell holds a BA degree in Economics from the College of Wooster and an M.B.A. from Pepperdine University Graduate School of Business. Mr. Donald E. Rindell, also known as Don, has been a Senior Director of Business Development at Amylin Pharmaceuticals, Inc., since 2005. Before moving to Amylin, Mr. Rindell served the industry as a highly sought-after independent consultant. Mr. Rindell has a successful consulting practice, during which time he served as Acting President of Medical Device Group, Inc., an acute care and respiratory company, Vice President of Business Development of CardioNet, Inc., a 'real-time'' 24/7 cardiovascular monitoring company and Vice President of Business Development of HandyLab, Inc., a molecular diagnostics and pharmacogenomics system company. His responsibilities included corporate marketing, mergers and acquisitions activities, product planning and new strategic initiatives. Prior to his consulting practice, he served as Vice President of Corporate Development & Strategic Planning of Advanced Tissues Sciences, Inc. ('ATS''), a La Jolla, California-based biotechnology company. Prior to his tenure at ATS, Mr. Rindell served as the Vice President for Global Business Management of Braun/Thermoscan, a division of The Gillette Company. At Braun/Thermoscan, he played a major role in building its medical diagnostics business. Mr. Rindell served as Executive Director of Sales and Marketing at Hybritech, a division of Eli Lilly. He has been a Director at TearLab Corporation since March 2006. He has been a Director of TearLab Inc., since March 2006. Mr. Rindell holds a BA degree in Economics from the College of Wooster and an M.B.A. from Pepperdine University Graduate School of Business.

Ophthalmic Pathology